FS-118 is under clinical development by F-star Therapeutics and currently in Phase II for Non-Small Cell Lung Cancer.

AFM-24I is under clinical development by Affimed and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 37% phase transition success rate (PTSR) ...

Half of the world's population is living in areas where dengue fever is present. Asian countries are most affected, reporting ...

INR:5114. 22bet how to deposit Promote provincial-level volume-based procurement + strictly investigate medical bribery! The disappearance of "golden drug ag ...

INR:5296. hungry dragon mod apk CD30/CD16A bispecific tetravalent antibody combined with K drug is superior to monotherapy in the treatment of R/R HL GE's t ...

INR:0527. blackjack tips On May 13, there were 3 newly confirmed cases, including 2 in Liaoning and 1 in Jilin. CD30/CD16A bispecific tetravalent antibody combined ...

free online gin rummy games no download iNKT cell therapy "newcomer" - bispecific antibodies From 0:00 to 7:00 on June 14, 8 new confirmed cases in Beijing were all related to Xinfadi CD30/CD16A ...

The global placebo-controlled trial involves nearly 80 subjects with early diffuse cutaneous systemic sclerosis.

Zura Bio Limited (Nasdaq: ZURA) ("Zura Bio"), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced the ...

Sinovac Biotech initiates phase ? trial on bivalent vaccine to treat hand foot and mouth disease: Beijing, China Tuesday, December 17, 2024, 18:00 Hrs [IST] Sinovac Biotech Ltd., ...

The Butantan Institute submitted a request to Anvisa (Brazil's National Health Surveillance Agency) on Monday (16) for the ...

SINOVAC has initiated a phase I/II clinical trial on its bivalent vaccine in China since September 2023. The results from Phase I/II clinical trial demonstrated that the vaccine candidate has ...